Lineage Cell Therapeutics, Inc.
(NYSE Amex Equities : LCTX)

( )
LCTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-1.67%292.231.4%$590.52m
AMGNAmgen, Inc.
0.07%234.011.3%$503.19m
GILDGilead Sciences, Inc.
1.04%67.781.0%$366.31m
REGNRegeneron Pharmaceuticals, Inc.
1.59%373.532.6%$302.52m
VRTXVertex Pharmaceuticals, Inc.
-0.12%220.001.9%$273.01m
ILMNIllumina, Inc.
-1.95%320.573.5%$231.88m
ARWRArrowhead Pharmaceuticals, Inc.
-3.73%68.2211.4%$207.81m
CLVSClovis Oncology, Inc.
-3.14%11.7214.7%$207.81m
ALXNAlexion Pharmaceuticals, Inc.
-1.53%109.502.0%$195.03m
EXASEXACT Sciences Corp.
-0.15%85.1724.0%$163.33m
AAgilent Technologies, Inc.
0.60%83.431.6%$159.09m
GBTGlobal Blood Therapeutics, Inc.
3.29%78.456.0%$142.09m
BLUEbluebird bio, Inc.
1.49%86.9714.2%$139.80m
BOLDAudentes Therapeutics, Inc.
-0.12%59.441.4%$134.26m
SGENSeattle Genetics, Inc.
-2.32%111.346.1%$128.54m

Company Profile

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.